Innoviva (INVA) Competitors

Innoviva (NASDAQ:INVA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Do analysts prefer INVA or ALKS?

Innoviva presently has a consensus price target of $40.33, suggesting a potential upside of 102.88%. Alkermes has a consensus price target of $40.92, suggesting a potential upside of 39.36%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alkermes	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Which has stronger earnings & valuation, INVA or ALKS?

Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$358.71M	3.48	$23.39M	-$1.01	-19.68
Alkermes	$1.51B	3.20	$367.07M	$2.09	14.05

Is INVA or ALKS more profitable?

Alkermes has a net margin of 23.30% compared to Innoviva's net margin of -16.15%. Alkermes' return on equity of 27.52% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	-16.15%	15.77%	8.41%
Alkermes	23.30%	27.52%	17.98%

Which has more risk & volatility, INVA or ALKS?

Innoviva has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Does the media favor INVA or ALKS?

In the previous week, Innoviva had 4 more articles in the media than Alkermes. MarketBeat recorded 17 mentions for Innoviva and 13 mentions for Alkermes. Alkermes' average media sentiment score of 0.86 beat Innoviva's score of 0.83 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders have more ownership in INVA or ALKS?

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 2.3% of Innoviva shares are owned by insiders. Comparatively, 4.4% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alkermes beats Innoviva on 12 of the 17 factors compared between the two stocks.